Publication | Closed Access

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial

Residual DiseaseSurgical OncologyMedicineMetronomic TherapyPhase Iii TrialPathologyImatinib InterruptionCancer TreatmentOncologyRadiation OncologyCancer Research